Camp4 Therapeutics (CAMP) Capital Expenditures (2023 - 2026)
Camp4 Therapeutics (CAMP) posted Capital Expenditures of $279000.0 for Q2 2025, up 6.08% sequentially from $263000.0 in Q4 2024, and up 933.33% YoY from $27000.0 in Q2 2024.
Camp4 Therapeutics (CAMP) Capital Expenditures (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has reported Capital Expenditures for 3 years, with the latest figure at $279000.0 in Q2 2025.
- Quarterly Capital Expenditures rose 933.33% year-over-year to $279000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $279000.0 (down 3.79% YoY) and the FY2025 annual result came in at $279000.0, down 36.73% from the prior year.
- Capital Expenditures advanced to $279000.0 in Q2 2025 per CAMP's latest filing, from $263000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $622000.0 in Q4 2023 and troughed at $27000.0 in Q2 2024.
- A 3-year average of $268400.0 and a median of $263000.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 57.72% in 2024, then soared 933.33% in 2025.
- Over 3 years, Capital Expenditures stood at $622000.0 in 2023, then plunged by 57.72% to $263000.0 in 2024, then climbed by 6.08% to $279000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $279000.0, $263000.0, and $27000.0 for Q2 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - | 298,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298,000.00 |
| Jun 30, 2026 | 298,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Jun 30, 2025 | 279,000.00 |
| Jun 30, 2025 | 279,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Dec 31, 2024 | 263,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Dec 31, 2023 | 622,000.00 |
| Dec 31, 2023 | 622,000.00 |